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ReviewMetal and Redox Modulation
of Cysteine Protein Function
metal ions such as Fe2/3, Zn2, Cd2, and Cu [6],
oxidized forms of cysteine, such as sulfenic and sulfinic
acids, have recently been implicated in the formation of
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1School of Biological and Chemical Sciences iron and cobalt complexes in proteins [7]. Sulfur can
2 Exeter Biocatalysis Centre accommodate a large number of bonds (through
University of Exeter changes in oxidation state) and geometries resulting in
Stocker Road very diverse structures with the same metal. For exam-
Exeter EX4 4QD ple, cysteine can function as a monodentate ligand to
United Kingdom bind metals, as is found in the nitrogenase iron protein
3 Exeter Antioxidant Therapeutics Limited from Azotobacter vinelandii, which contains a [4Fe-4S]
The Innovation Centre cluster where each iron is coordinated to a separate
University of Exeter cysteine ligand [8]. Cysteine can bind more than one
Rennes Drive type of metal in a cluster, as exemplified by the recent
Exeter EX4 4RN characterization of carbon monoxide dehydrogenase
United Kingdom from Carboxydothermus hydrogenoformans, which
contains an active site [Ni-4Fe-5S] cluster where again
each metal is ligated by a separate cysteine [9]. Cysteine
can also act as a bidentate bridging ligand, as seen in theIn biological systems, the amino acid cysteine com-
active site of the [NiFe] hydrogenase from Desulfovibriobines catalytic activity with an extensive redox chem-
vulgaris Miyazaki F, which contains four cysteine sulfuristry and unique metal binding properties. The interde-
and four nonprotein sulfide (S2) ligands coordinated topendency of these three aspects of the thiol group
the cluster. Two of the cysteines act as bridging ligandspermits the redox regulation of proteins and metal
between the iron and nickel, and the remaining twobinding, metal control of redox activity, and ligand
cysteines coordinate the nickel [10]. Cysteine can alsocontrol of metal-based enzyme catalysis. Cysteine
act as a bridging ligand between different subclusters.proteins are therefore able to act as “redox switches,”
The iron-only hydrogenase from Clostridium pasteuria-to sense concentrations of oxidative stressors and
num contains an [4Fe-4S] subcluster coordinated byunbound zinc ions in the cytosol, to provide a “storage
three cysteines and has a fourth coordinating cysteinefacility” for excess metal ions, to control the activity
ligand that bridges to the [2Fe] subcluster [11]. Theseof metalloproteins, and to take part in important regu-
versatile metal binding modes of the cysteine ligandlatory and signaling pathways. The diversity of cys-
are exemplified by the protein metallothionein, whichteine’s multiple roles in vivo is equally as fascinating
contains two zinc/sulfur clusters. The  cluster (Zn4Cys11)as it is promising for future biochemical and pharma-
binds four zinc ions with six terminal and five bridgingcological research.
cysteine ligands, whereas the  cluster (Zn3Cys9) binds
three zinc ions with six terminal and three bridging cys-Introduction
teine ligands [12]. The resulting diversity in cysteine bio-The amino acid cysteine endows proteins with an excep-
chemistry gives rise to an extraordinary interplay of cata-tional biochemistry due to the unique chemical charac-
lytic activity, redox behavior, and metal binding interistics of its thiol group [1, 2]. Its nucleophilicity, redox
proteins.activity, and metal binding properties make cysteine an
To approach this complex interaction in a systematicessential building block of many proteins and a key
manner, this review starts with the chemistry of the thiolcatalytic component of enzyme function. Considering
group, i.e., its nucleophilicity, redox activity, and metalredox activity and posttranslational modifications, cys-
teine residues with sulfur in numerous oxidation states binding properties. These three properties are then con-
have been identified in proteins (Figure 1). Among them, sidered within the context of mammalian biochemistry.
the thiol and disulfide oxidation states are probably best Rather than providing a comprehensive summary of cys-
known, but modifications such as sulfenic, sulfinic, and teine biochemistry, the review focuses on situations
sulfonic acids, disulfide-S-oxides, and a range of sulfur- where these three properties “coincide” in proteins, giv-
centered radicals play an increasingly important role in ing rise to redox control of cysteine’s catalytic activity,
biochemistry [2–4]. This variety of oxidation states is redox control of metal binding, metal control of cys-
matched by the number of different redox mechanisms teine’s catalytic activity, and cysteine control of a met-
available to sulfur. For example, the thiol(ate) group can al’s catalytic activity.
undergo nucleophilic attack, electron transfer, hydride Since these scenarios are illustrated by describing
transfer, hydrogen radical transfer, and oxygen atom selected highlights, it should be mentioned from the
transfer reactions [1, 5]. outset that several of the examples discussed here are
An additional property of cysteine is its unique metal still under investigation and are, therefore, not entirely
binding ability. While the thiolate ligand strongly binds uncontroversial. In addition, some equally interesting
aspects of cysteine biochemistry (e.g., thiol:disulfide ox-
idoreductases, iron/sulfur proteins [13]) cannot be ad-*Correspondence: c.jacob@ex.ac.uk
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Figure 1. Important Posttranslational Cyste-
ine and Methionine Modifications Found in
Peptides and Proteins
Formal oxidation states are shown in
brackets.
(a) Cysteinyl radical (1), (b) cystine (i.e.,
“cysteine disulfide”) (1), (c) cysteine sulfenic
acid (0), (d) cysteine sulfinic acid (2), (e) cys-
teine sulfonic acid (4), (f) cysteine-S-sulfate
(5), (g) cystine-S-monoxide (1), (h) cystine-
S-dioxide (3), (i) methionine disulfide radical
cation with a three electron bond (3/2), and
(j) a tetrahedral ZnCys4 complex (2). Further
details are given in the text. For a more de-
tailed list of cysteine modifications, see [5].
dressed here, and literature references of recent reviews and outlook on future developments in this emerging
area of biochemical research.in these areas are provided throughout the text.
The first section of this review (Redox Control) looks
at examples of how catalytic activity is controlled by Redox Control of Cysteine’s Catalytic Activity
the redox state of active site cysteine residues. Changes A number of cysteine-containing proteins such as the
in the sulfur oxidation state of cysteine influences the thioredoxins (Trx) and enzymes such as glutathione re-
activity of many proteins [2, 14]. The details of selected ductase (GR) require redox-active cysteine residues for
examples discussed in the text are summarized in Table their activity [15–18]. In contrast, a change in the oxida-
1. It also has dramatic effects on the amino acid’s metal tion state of sulfur must be avoided in redox-sensitive
binding properties, and these are discussed in the sec- cysteine proteins in which the reduced state of the thiol
ond section (Ligand Oxidation and Metal Release). While is an absolute requirement for activity. Oxidative enzyme
the first two sections focus on the redox control of metal inhibition is frequently observed in proteins under condi-
binding and differences between ligand-controlled tions of oxidative stress, where reversible disulfide for-
metal activity and metal-controlled ligand activity in pro- mation and irreversible cysteine oxidation to sulfinic
teins, the interaction of cysteine and metals is also im- acids has been observed [19, 20].
portant from the metal’s point of view. Zinc/sulfur com- More recently, the oxidative modification of cysteine
plexes play a prominent role in the maintenance of zinc residues in proteins has been implicated in cellular sig-
homeostasis inside the cell, an emerging regulatory naling and regulatory pathways [20]. This notion is highly
mechanism that is discussed in the third section (Regu- important, since it assigns a specific biochemical role to
lation of Zinc Homeostasis). oxidative, posttranslational cysteine modification (e.g.,
A deeper understanding of these control mechanisms during oxidative stress [21]) that goes beyond the appar-
has also stimulated the exploration of new avenues in ently “random” cysteine oxidation frequently observed
pharmacological research. The fifth section (Drug De- under aerobic conditions in vitro. The significance of
sign) briefly considers recent advances in the design of controlled cysteine oxidation is further underlined by
drug prototypes that either mimic or interfere with the the increasing number of cysteine enzymes that redox
processes discussed in the sections Redox Control, Li- cycle between the thiol and other, “unusual,” sulfur oxi-
gand Oxidation and Metal Release, and Regulation of dation states such as the thiyl radical and sulfenic acid. It
is therefore helpful to briefly consider the most commonZinc Homeostasis. The Summary provides a brief recap
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Table 1. Control of Cysteine Protein Activity
Role of Cysteine Redox States of
Protein Residue Sulfur Role of Metal Ions Modulation of Activity
ADH 1 catalytic and 1 thiol catalytic (Zn2) cysteine oxidation (↓)
structural zinc/sulfur
complex
Zn2 removal (↓)
Agro-bacterial essential disulfide disulfide unknown disulfide formation (↑)
esterase
CPA none N/A 1 catalytic, 1 inhibitory D-cysteine (↓)
Zn2 site
Zn2 removal from
inhibitory (↑) or catalytic
site (↓)
Cd2 exchange at catalytic
site (↓)
Caspase-3 catalytic thiol inhibitory (Zn2) Zn2 (↓)
chelator (↑)
cysteine oxidation (↓)
GAPDH catalytic thiol inhibitory (Zn2) Zn2 (↓)
chelator (↑)
cysteine oxidation (↓)
MMP inhibitory thiol catalytic (Zn2) cysteine (pro-MMP) (↓)
cysteine oxidation (↑)
metal ions (?)
TIMP binding (↓)
Zn2 chelators (↓)
MT zinc/sulfur complexes thiol storage (Zn2) oxidative metal release
oxidative stress sensor (?) metal exchange (Cd2)
MTF-1 CCHH zinc finger thiol Zn2 sensor oxidative
Zn2 release (?)
Nox catalytic thiol/sulfenic unknown unknown
acid
NHase ligand (Fe3,Co3) sulfenic, sulfinic catalytic sulfenic acid modifiers (↓)
acid
PTP catalytic thiol inhibitory (Zn2) Zn2 (↓)
chelator (↑)
cysteine oxidation (↓)
Sp1 CCHH zinc finger thiol structural (Zn2) oxidation (↓)
Zn2 chelator (↓)
A selection of cysteine proteins whose activity is significantly modulated by redox processes, adventitious metal binding, chelators, and thiols.
Details are found in the text.
oxidation pathways and redox modifications of cysteine teins such as human glutathione disulfide reductase
(GR) and thioredoxin reductase (TrxR), where a two-found in proteins.
Cysteine Oxidation in Proteins: Pathways electron transfer from FADH2 reduces a cystine disulfide
bond to two cysteine thiols [18, 26]. Chemically, electronand Species
Numerous oxidized cysteine species have been found transfer to a disulfide is a reversible reaction that can
be studied electrochemically [27–29], while other redoxin vivo and in vitro, among them thiyl radicals, disulfides,
persulfides, sulfenic acids, sulfinic acids, sulfonic acids, mechanisms of sulfur are considerably more difficult
to investigate. From a mechanistic point of view, it ispolysulfides, selenosulfides, disulfide-S-monoxides, and
disulfide-S-dioxides (Figure 1). The formation and (bio)- interesting to note that the oxidation of two thiols to a
disulfide can proceed via two one-electron transferschemical properties of these thiol modifications provide
an extensive field of biochemical research on its own with subsequent dimerization, while the reduction of the
disulfide proceeds via one two-electron transfer.that has been recently reviewed [4, 22]. In short, different
oxidative modifications of cysteine residues in proteins In many proteins, cystine reduction involves electron
transfer while cystine formation does not. This apparentoccur as a result of the thiol(ate) group’s ability to trans-
fer electrons and atoms, act as a nucleophile, and un- paradox is the result of cysteine’s ability to participate
in different redox mechanisms. In GR, electron transferdergo radical reactions. The following examples illus-
trate the variety of redox mechanisms and resulting reduces an active site disulfide that is formed via a thiol/
disulfide exchange reaction with glutathione disulfideoxidation states found for cysteine in vivo.
The low redox potential of cysteine (ranging from (GSSG). This process consumes NADPH and produces
reduced glutathione (GSH). GR therefore connects thearound 270 mV to 125 mV versus NHE in most pro-
teins [23, 24]) allows rapid electron transfer from cys- cell’s energy metabolism (NADPH) with the maintenance
of its redox balance, determined by the GSH:GSSG ratioteine, resulting in thiyl radical and disulfide formation
[25]. The reverse reaction is frequently observed in pro- (usually in the range of 100:1) [30, 31].
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Electron transfer from cysteine is observed between the case of Nox, also involving the formation of peroxy-
flavin). The reduction of the sulfenic acid can proceedits thiol group and metal ions such as Cu2 and Fe3.
Cysteine residues in the zinc/sulfur protein metallothio- via two distinct mechanisms both found in vivo: via an
exchange reaction involving two thiol equivalents (e.g.,nein (MT), for example, are directly oxidized by cyto-
chrome c [32], while other cysteine oxidation pathways Prx) or via hydride transfer from FADH2 (e.g., Npx and
Nox) [39].in the presence of metal ions involve radical species. In
the absence of normal substrate, redox-active metal Most intracellular disulfides are, however, formed and
broken by a mechanism not involving any electron orions in metalloenzymes can undergo electron transfer
reactions with oxygen, resulting in the generation of oxygen atom transfer. Thiol/disulfide exchange reac-
tions are nucleophilic substitution reactions of thiolatesuperoxide and hydrogen peroxide. In addition, hy-
droxyl radicals can be formed via Fenton-type chemistry RS on the disulfide R’SSR’, resulting in a mixed disul-
fide RSSR’ (with a formally oxidized RS thiol) and re-from hydrogen peroxide and metal ions [33].
Cysteine residues are particularly susceptible to these duced R’S. These reactions are widespread in vivo
(e.g., found in thiol:disulfide oxidoreductase enzymesoxidative stressors, forming a variety of posttransla-
tional modifications. The one-electron oxidation of cys- [15]) and also contribute to very important posttransla-
tional protein modification processes.teine by Fe3 or Cu2 ions and radical species such as
the hydroxyl radical, superoxide, and nitric oxide initially The formation of mixed disulfides between protein
thiols and low molecular mass thiols such as cysteineresults in (thiyl, RS•) radical formation. The latter can
combine with a second radical to form nonradical spe- and GSH (S-glutathionylation) is thought to be part of
cellular signaling [19]. Changes in the cellular redox bal-cies such as disulfides (RSSR), sulfenic acids (RSOH),
sulfinic acids (RS(O)OH), or, in the case of NO, an ance trigger signal transduction pathways by modifying
the oxidation state of cysteine residues in participatingS-nitrosylated cysteine (RSNO) (Figure 1).
This complex interplay between cysteine and redox- proteins, shuttling between cysteine, cysteine disul-
fides, cysteine sulfenic, and cysteine sulfinic acids. Re-active metal ions is exemplified in the case of phenylala-
nine-sensitive 3-deoxy-D-arabino-heptulosonate-7-phos- dox modifications can exert a variety of effects on pro-
teins ranging from inactivation of a catalytic residuephate synthase (DAHPS) from Escherichia coli. This
enzyme requires a Cu2 cofactor and is unstable in the (e.g., mammalian protein tyrosine phosphatase [PTP])
to extensive structural changes (e.g., Escherichia coliabsence of its substrate [34]. The auto-inhibition pro-
cess is ascribed to the oxidation of two cysteine resi- OxyR, Figure 2) [19, 41].
In addition, S-thiolation reactions have recently beendues (Cys61 and Cys328) at the active site to cysteinyl
radicals. The reaction is initiated by one-electron trans- considered as a temporary protective mechanism uti-
lized by enzymes during oxidative stress that preventsfer from cysteine to Cu2, forming Cu and the first
cysteinyl radical. A hydroxyl radical is produced by the irreversible modification of their critical active site thiol
[2]. Mammalian Protein kinase C, creatine kinase, gluco-reaction of Cu and H2O2, regenerating Cu2. The hy-
droxyl radical then reacts with the second cysteine resi- corticoid receptors, and DNA binding by transcription
factors such as c-Jun are a few examples of functionallydue, forming another cysteinyl radical and water. The
resulting two cysteinyl radicals dimerize to form a disul- very diverse proteins, all of whose activity are affected
by protein S-thiolation/glutathionylation [42–45].fide. This is confirmed by incubation with DTT, which
restores enzymatic activity [34]. Like S-glutathionylation, other nucleophilic substitu-
tion reactions also result in reversibly modified cysteineThe radical biochemistry of cysteine itself is becoming
increasingly important [3]. Cysteine-based radicals can residues that might play a role in enzyme regulation.
Proteins such as mammalian hemoglobin, albumin, glyc-be formed by long-range one-electron transfer reactions
and short-range hydrogen atom abstraction and include eraldehyde 3-phosphate dehydrogenase (GAPDH), cas-
pase, PTPs, and alcohol dehydrogenase (ADH) can bespecies such as thiyl, sulfinyl, and sulfonyl radicals, di-
sulfide radical anions, and a range of peroxyl radicals, oxidatively modified by S-nitrosylation to form R-SNO
species [46–50]. This reaction alters the activity of thesemany of which are likely to exist during oxidative stress
and in the presence of redox-active metal ions [4, 35]. proteins, suggesting that this is a possible method of
protein regulation in vivo—in line with the known func-Sulfur-centered radicals are also increasingly found as
part of enzymes’ catalytic cycles (e.g., RNRase super- tion of NO as a cellular signaling molecule. The presence
of large amounts of GSH in cells implies that nitrosoglu-family, E. coli, pyruvate formate lyase [PFL], and Thauera
aromatica benzylsuccinate synthase [BSS] [36–38]), tathione (GSNO) is another important form of nitric oxide
in vivo. GSNO can be nucleophilically attacked by pro-where they provide an exciting new area of biochemical
radical research. teins’ cysteine residues at its sulfur or nitrogen atom,
resulting either in protein S-nitrosylation or S-glutathio-In contrast, peroxidation of thiols leads to the forma-
tion of sulfenic and sulfinic acid species whose proper- nylation as observed for phosphorylase b, H-ras, and
carbonic anhydrase III [51].ties are very different from the disulfide state. Such oxy-
gen atom transfer reactions are observed in redox Although many cysteine modifications irreversibly
abolish protein function, the reversible (e.g., S-thiola-enzymes such as Streptococcus faecalis NADH peroxi-
dase (Npx), NADH oxidase (Nox), and human peroxire- tion, sulfenic acid formation) and some of the irreversible
(e.g., sulfinic and sulfonic acid formation) processes aredoxins (Prx) [39, 40], which function via a cysteine (Cys-
SH)/cysteine sulfenic acid (Cys-SOH) redox couple. The increasingly considered as regulatory processes rather
than just random inhibition of protein activity [2, 20,catalytic cysteine residues of these enzymes are oxi-
dized by hydrogen peroxide to cysteine sulfenic acid (in 39]. This regulatory role is becoming important during
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extracellular matrix during tumor cell invasion [56]), and
the calpains (implicated in cytoskeletal remodeling pro-
cesses, cell differentiation, apoptosis, and signal trans-
duction) [57].
The catalytic mechanism of cysteine proteases based
on papain has been reviewed by Brocklehurst et al.
[58]. It is similar to that of the serine proteases, where
cysteine acts as a nucleophile and a histidine residue
acts as a proton donor (Figure 3A for general mecha-
nism). Nucleophilic attack by cysteine results in forma-
tion of the first tetrahedral species followed by formation
of an acyl enzyme intermediate and release of the amine
product. Attack by a water molecule results in formation
of the second tetrahedral species, which is followed by
polypeptide chain release, leaving the enzyme back in
its original state to carry out another round of catalysis.
This mechanism is based on a combination of covalent
and acid-base catalysis. In addition to the cysteine-
histidine catalytic “diad,” some proteases contain an
acidic residue, usually aspartic acid or asparagine [59].
This residue is suggested to stabilize and orient the
imidazolium ring and favor the movement of positive
charge from the cysteine to histidine residue of the ac-
tive site.
The active site cysteine residue can be readily oxi-
dized as observed from the additional electron density
associated with this residue in several high-resolution
crystal structures such as archaeal GAPDH and pyrroli-
done carboxyl peptidase (PCP) [60, 61]. The in vivo impli-
cations of this oxidative inhibition of protease activityFigure 2. A Diagrammatic Representation of the Crystal Structure
of OxyR are particularly important in the case of the caspase
Structural changes of the “redox switch” OxyR upon oxidation (re- enzymes, cysteine proteases located in the cytoplasm,
duced and oxidized forms of OxyR, PDB IDs 1I6A and 1I69, respec- and mitochondria, which play a critical role in the apo-
tively) [175]. The mechanism of activation of OxyR involves the hy- ptotic pathway. Human caspase-3 is directly involved
drogen peroxide-induced formation of a disulfide between Cys199 in the process of programmed cell death, where it inacti-
and Cys208. The bulk of the structure (white) is unaffected by this
vates proteins involved in cell repair and homeostasis.activation mechanism. In the reduced form (red; Cys199 mutated
The crystal structure for this protease is now availableto Ser), these two residues (green) are 17 A˚ apart, and in the oxidized
form (blue), formation of the disulfide (yellow) results in major struc- [62]. The mature form of the enzyme is a complex of
tural rearrangement that includes formation of a new  strand. The two polypeptide chains: p12 is involved in substrate
figure was produced using QUANTA2000 [176].  helices are shown binding and p17 provides the catalytic residues. Oxida-
as cylinders,  sheets as arrows, and the cysteine and cystine resi- tive changes to caspase activity are primarily mediated
dues are shown as liquorice.
by NO and are also dependent on the presence of free
iron and the intracellular redox potential [63]. Mitochon-
normal cell function, apoptosis, aging processes, and drial caspases-3 and -9 are frequently S-nitrosylated at
pathological conditions such as oxidative stress [2, 39, the active site cysteine, a process that inhibits proteo-
52–54]. Among the numerous redox-sensitive cysteine- lytic activity and their ability to induce apoptosis and
containing proteins, cysteine peptidases and dehydro- inflammation [64]. The majority of cytoplasmic enzymes,
genases best exemplify oxidative and redox control. however, are not nitrosylated, which suggests that
These enzymes will therefore be discussed in more movement of these caspases into the cytoplasm does
detail. not favor stability of S-NO, possibly a method of revers-
Redox Control of Cysteine Proteases ible caspase activation by denitrosylation [65]. This
and Dehydrogenases underlines the notion that oxidative cysteine modifica-
Many enzymes utilize a catalytic cysteine residue in the tion is not a random process resulting in protein inhibi-
form of a thiolate anion as a nucleophile in reactions tion, but rather a process suitable to control enzymatic
ranging from thiol exchange redox reactions (e.g., Trx, activity within the redox environment of the cell.
GR) to proteolytic reactions as found in cysteine prote- In contrast to this kind of reductive activation, other
ases. The family of cysteine proteases consists of a hydrolytic enzymes appear to be activated by the oxida-
range of different enzymes with different overall tertiary tion of cysteine residues leading to the formation of
structures and distinct biological functions. These in- disulfide bonds essential for enzyme activity [66]. Disul-
clude the human apoptosis protease caspase-3, ca- fide formation is considered to be a common mechanism
thepsin F (implicated in processing of the invariant chain of protein stabilization and folding, and primarily pro-
associated with Major Histocompatability Complex teins exported from the cell are rich in disulfide bonds.
These are formed at the correct positions in the folded[55]), cathepsin B (implicated in the remodeling of the
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Figure 3. Catalytic Cycles of Cysteine Prote-
ases and Dehydrogenases
Panel (A) shows cysteine proteases, and
panel (B) shows dehydrogenases. Initial at-
tack of the cysteine thiolate anion results in
the formation of a tetrahedral species (A).
Collapse of the tetrahedral species results in
the formation of the acyl-enzyme (thiolester)
intermediate (B). Nucleophilic attack by either
the phosphate or hydroxyl anion results in
the formation of the carboxylic acid (C) or
phosphoester (D) and regeneration of the thi-
olate anion [58, 177].
protein by enzymes such as the thiol:disulfide oxidore- active site. The latter is cleaved by nucleophilic attack of
phosphate, resulting in the formation of a phosphoesterductase enzyme protein disulfide isomerase (PDI) found
in the endoplasmic reticulum of eukaryotic cells [67]. with regeneration of the active site cysteine. Related
enzymes, such as yeast aldehyde dehydrogenaseOxidative activation by disulfide bond formation is,
however, a novel mechanism that has been recently (ALDH), follow a similar redox mechanism, and these
enzymes are inhibited by oxidizing agents that modifyproposed to occur in an agrobacterial esterase enzyme
that has been studied crystallographically at atomic res- the catalytically active cysteine residue. Among those
biologically relevant oxidizing species, peroxynitrite [68]olution [66]. A disulfide bond between two adjacent resi-
dues needs to be formed to complete the “oxyanion and “reactive sulfur species” [4, 69] have recently been
investigated in the context of dehydrogenase regulationhole” for binding of the tetrahedral intermediate in the
reaction mechanism. It is possible that human enzymes during oxidative stress.
While the effects of oxidation on the activity of theseare also regulated in this way, and kinetic studies com-
bined with high-resolution enzyme structures will ex- proteins are well understood, the formation of “unusual”
oxidation states in the sheltered environment of the ac-plore this issue further.
In a manner similar to cysteine proteases, several de- tive site has led to a few surprises. A stable sulfenic
acid has been observed in the active site of papain [70,hydrogenase enzymes are affected by the redox state
of an active site cysteine residue. Mammalian muscle 71] as well as other cysteine proteases [72] and GAPDH
[73, 74]. Cysteine sulfenic acids also form part of cata-GAPDH catalyzes the oxidation and subsequent phos-
phorylation of aldehydes to acyl-phosphates while re- lytic redox cycles in enzymes. Crystallographic data
from the native oxidized crystal structures of Strepto-ducing NAD to NADH. Its catalytic cycle involves a
crucial hydride transfer step that requires an activated coccus faecalis NADH oxidase and NADH peroxidase
and human peroxiredoxins have shown the formationaldehyde substrate. The enzyme’s active site contains
a cysteine that attacks the aldehyde to form a highly of a cysteine sulfenic acid at the active site [19, 39,
70, 75].reactive tetravalent thioether intermediate (Figure 3B).
A hydride is transferred to NAD to form a thioester at the The active sites of these enzymes are therefore able
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to sustain the formation of the highly unstable cysteine thiuram disulfide, antabuse), have been used in the past
to treat alcoholism by inhibiting ADH (and other en-sulfenic acid, a thiol modification that is notoriously diffi-
cult to achieve in chemical synthesis [76–78]. In contrast, zymes) in patients [82, 83].
It should be noted, however, that neither cysteineoveroxidation of the sulfenic acid to the more stable
sulfinic acid provides an additional sulfur acid modifica- oxidation nor metal removal from active sites is always
detrimental to enzyme activity, as the example of thetion that is, for example, found in bacterial nitrile hydra-
tase (NHase) from Rhodococcus sp N-771 [7]. agrobacterial esterase enzyme has already illustrated.
The next section discusses examples of enzyme activa-While caspase-3 and GAPDH activity are directly af-
fected by the modification of a catalytic cysteine, zinc/ tion by removal of unwanted metals from the active site.
Ligand Releasesulfur enzymes frequently lose their catalytic activity by
oxidative release of the catalytic metal ion. Cysteine In contrast to these hydrolases, the matrix metallopro-
tease (MMP) family of proteases is activated by cysteineoxidation is not always, however, detrimental to enzyme
activity, as the next section illustrates. oxidation. For normal growth and development, cells
must interact with the extracellular matrix (ECM) that is
continually modified by proteolytic systems. The latter
Ligand Oxidation and Metal Release alter the constitution of the ECM structure and therefore
in Metalloproteins regulate cell growth, differentiation, and cell death. Un-
Several metalloproteases and mammalian liver alcohol controlled degradation leads to the development of
dehydrogenase (ADH) contain an active site zinc/sulfur pathological conditions including inflammation, arthritis,
complex that is under redox control. There are two pos- and cancer [84]. Human MMPs are zinc-dependent en-
sible regulatory scenarios. First, the role of the thiolate dopeptidases able to cleave a variety of ECM compo-
ligand is to bind a zinc ion essential for catalytic activity. nents. They are synthesized in an inactive form inside
Oxidation of the ligand would result in loss of activity the cell and exported to the ECM, where they are acti-
due to metal release from the active site. Second, the vated by proteolytic cleavage of the propeptide region.
ligand occupies a coordination site on the metal that The molecular weight ranges from 62 to 130 kDa be-
is essential for substrate binding. On oxidation of this tween various species and proteolyzed forms of the
ligand, the binding site for substrate becomes available, enzyme. Recent studies have shown that the activity of
leading to activation of the enzyme (on condition that these enzymes can also be regulated by thiol com-
the other ligands, such as histidine, are not affected by pounds and redox reactions [85–87].
oxidation). The oxidative disintegration of metal/sulfur MMPs are organized into three major domains based
complexes can, therefore, be seen from two different on structure: a catalytic domain, a carboxy-terminal
perspectives: enzyme inhibition by release of an essen- hemopexin-like domain, and a propeptide region. The
tial metal ion and enzyme activation by release of a catalytic domain of MMP enzymes contains one cata-
(superfluous) ligand. The first scenario is exemplified by lytic and one structural zinc ion and at least one calcium
ADH and metallo--lactamases, while the second plays ion [84]. The catalytic zinc ion is bound by three highly
a major role in the regulation of the activity of matrix conserved histidine residues. It has a vacant coordina-
metalloproteases (MMPs). tion site that is occupied in the active enzyme by a highly
Zinc Release polarized water molecule that acts as the nucleophile
Mammalian ADH catalyzes the oxidation of ethanol to during the catalytic cycle of the enzyme. In the inactive
acetaldehyde under alkaline conditions. The most stud- form, however, this coordination site is occupied by a
ied is horse liver ADH, which is an 80 kDa dimeric enzyme thiolate ligand from the propeptide region (Figure 4A).
with two tightly bound zinc atoms (one catalytic and The latter is 80–90 amino acids in length and contains
one structural) and one NADH binding site per subunit. a redox-sensitive cysteine residue within the highly con-
The structural zinc is bound by Cys97, Cys100, Cys103, served PRCGXPD sequence, which interacts with the
and Cys111 in a tetrahedral geometry, while the catalytic catalytic zinc, hence functioning as a “stopper” of activ-
zinc ion is ligated by Cys46, Cys174, His67, and a water ity [84].
molecule with an additional bond to Ser48. As a ligand, The biological role and mechanism of oxidative MMP
the water molecule is easily exchangeable for substrate. activation is still under investigation. It was initially found
Crystallography has shown that in the enzyme-NAD- that pro-MMP-1, -8, and -9 were activated by peroxyni-
alcohol ternary complex [79], the OH group of the alcohol trite in the presence of GSH, indicating that the S-glu-
binds to the zinc through an inner coordination sphere, tathionylation of the propeptide region (via the formation
with the side chains of Ser48 and Phe93 effectively lock- of glutathione disulfide-S-monoxide) was taking place
ing the alcohol into position for hydride transfer from [87]. More recently, it has been found that pro-MMP-9 is
the alcohol to the NAD [80]. activated by S-nitrosylation and then induces neuronal
Not surprisingly, the high number of cysteine ligands apoptosis in vitro [85]. In related in vivo experiments,
makes the zinc binding sites in ADH sensitive toward MMP-9 colocalized with neuronal nitric oxide synthase
oxidation that causes the release of zinc and subse- during cerebral ischemia. Mass spectrometry identified
quently enzyme inhibition [69, 81]. Like GAPDH, ADH the active derivative of MMP-9, both in vitro and in vivo,
is readily inhibited by NO, and nitrosothiolation at the which was found to contain a stable sulfinic or sulfonic
catalytic site is accompanied by zinc release [48]. From acid, whose formation was initiated by S-nitrosyla-
a pharmacological point of view, oxidation and subse- tion [85].
quent inhibition of liver ADH can be used to sensitize Similarly, the activation of pro-MMP-7 in the artery
the organism against ethanol. As a consequence, thiol- wall can be controlled by myeloperoxidase and the pro-
duction of hypochlorous acid [86]. Mass spectrometricspecific oxidizing agents, such as disulfiram (tetraethyl-
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Figure 4. Ligand Control of MMP Activity
Activity of these zinc enzymes can be modu-
lated by ligand binding in two different ways.
Part (A) shows inhibition of pro-MMP2 by co-
ordination of a cysteine ligand of the prodo-
main to catalytic zinc (PDB ID 1GXD) [178].
The formation of a metal-ligand bond is not,
however, a requirement, and part (B) in-
dicates how the formation of the Mem-
brane-type MMP1/TIMP complex results in
blockage of substrate access to the active
site (PDB ID 1BUV) [179]. Figure produced
using QUANTA2000 [176].
studies of human atherosclerotic lesions (both in vitro kDa that contain several conserved cysteine residues
(12 in the case of TIMP-1 and TIMP-2), all of which areand in vivo) have shown that the thiol residue of the
cysteine in the enzyme’s prodomain was converted to in the disulfide state. These disulfides are essential for
the structural integrity of the TIMP proteins and theira sulfinic acid. As such, thiol oxidation was associated
with autolytic cleavage of pro-MMP-7, suggesting that inhibitory activity. The crystal structure of the complex
between human stromelysin-1 (MMP-3) and humanoxidation activates the latent enzyme [86].
Like the MMP enzymes, the human zinc protease car- TIMP-1 shows that the amino group of the TIMP cysteine
residue (Cys-1) blocks the active site zinc of MMP-3,boxypeptidase A is also inhibited by “undesired ligands”
such as D-cysteine, which replaces the hydroxyl ion at inhibiting its activity by exclusion of water [89]. A similar
interaction is observed for the cysteine residue (Cys-1)the active site [88]. Oxidative removal of thiols from
the active site of this enzyme has, to the best of our of TIMP-2 binding to membrane-type-1 MMP (Figure
4B). Paradoxically, while oxidation of the inhibitory thio-knowledge, not yet been studied. Neither has thiol ligand
removal by excess zinc ions, a possible theoretical alter- late ligand in pro-MMPs activates the enzyme, reduction
of the disulfide bonds in TIMP would, at least hypotheti-native to ligand oxidation.
MMPs are also inhibited by a range of proteins known cally, also lead to activation via changes in TIMP struc-
ture and the resulting dissociation of the MMP-TIMPas “tissue inhibitors of metalloproteases” (TIMPs) [89].
Interestingly, TIMPs are peptides of approximately 20 complex.
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It should be mentioned that, while oxidative MMP rapid cysteine oxidation and subsequent irreversible en-
zyme inhibition that would otherwise occur under theseactivation provides certain similarities with the oxidative
activation of the agrobacterial esterase enzyme men- conditions.
The interaction of cysteine proteins with free metaltioned above, the activation pathways are completely
different. MMP activation involves ligand removal from ions clearly warrants further investigations. It also em-
phasizes the importance of a tightly controlled metala catalytic metal, while the esterase is activated by the
formation of an essential disulfide bond. The following homeostasis inside the cell.
section looks at yet another activation mechanism
based on the dismantling of an “unwanted” metal/zinc
Regulation of Zinc Homeostasiscomplex—this time with the metal (and not the ligand)
Oxidative disintegration of metal complexes has alreadyas inhibitor.
been mentioned as an inhibitory mechanism for ADHMetal Poisoning
and as part of a possible activation mechanism for MMPHydrolases and dehydrogenase enzymes with active
proteins. Oxidative regulation of metal binding is partic-site cysteines provide an interesting paradox: while
ularly important in the control of the level of availablesome of these enzymes require zinc ions for their activity
metal ions inside the cell. Metal trafficking and the intra-(e.g., metallo-lactamases, ADH), others are inhibited by
cellular control of metal homeostasis have become in-zinc (e.g., caspase-3, GAPDH) [90–92]. Zinc inhibition is
creasingly important topics in biochemistry during theobserved when metal ions bind directly to cysteine at
last decade [100] and the regulatory system for main-the active site, and this unwanted metal binding is of
taining the intracellular zinc homeostasis is slowly be-particular interest since it is frequently an unwelcome
coming apparent. This section, therefore, discusses theresult of cysteine chemistry. While the thiolate group in
emerging role of zinc/sulfur bonds in the sensing andenzymes such as GAPDH and caspase-3 catalytically
storage of zinc, with focus on the role of metallothioneinacts as a nucleophile, it is by definition also an excellent
in maintaining the cellular zinc homeostasis.ligand for zinc ions. “Random” zinc binding to cysteine
Thionein, Metallothionein, and the Intracellularresidues in these proteins is therefore frequently ob-
Zinc Homeostasisserved in vitro and, as the inhibitory effects of zinc ions
Metallothionein is a major zinc binding protein that ison fungal growth show, might play a role in vivo [93].
thought to play a key role in maintaining the intracellularOther divalent metals such as copper and cadmium have
zinc homeostasis. An important property of the MT zincalso been shown to inhibit GAPDH from Xenopus laevis
store is that it can provide zinc where needed and scav-and Pleurodeles waltl by binding to the active site cys-
enge heavy metals such as cadmium and mercury [101].teine [94].
Although discovered more than 45 years ago [102], theA second mechanism of metal poisoning is the substi-
precise biological role of MT has long remained illusivetution of the catalytic metal by an inhibitory metal, lead-
[103]. It has now been shown that the expression ofing to loss of enzyme activity. In human porphobilinogen
MT’s apo-form, thionein, is controlled by a feedbacksynthase, for example, Pb2 displaces the active site
mechanism for the control of free zinc ions in the cytosol.Zn2, which is ligated by cysteine. Pb2 disfavors sub-
This mechanism involves sensing the concentration ofstrate binding, which in turn leads to loss of activity [95].
unbound (“free”) zinc by a zinc finger protein, expressionIt should be mentioned that a third mechanism for
of thionein, zinc storage in MT, zinc transfer, and, possi-protein inhibition by metal ions is based on genuine
bly, oxidative zinc release (Figure 5) [104].inhibitory sites in enzymes. These sites are different from
It should be mentioned from the outset that this regu-the active site and do not necessarily involve cysteine
latory mechanism is still under investigation and theresidues. Carboxypeptidase A, for example, has an in-
precise function(s) of MT in vivo are still a matter ofhibitory zinc binding site, and occupation of this site
significant controversy [104]. This also includes the linkby zinc ions reduces enzyme activity [96–98]. A fourth
of MT with the two families of zinc transporters thatmechanism involves cysteine oxidation by redox-active
have been identified in eukaryotes, the Cation Diffusionmetal ions and has been discussed in the Redox Control
Facilitator (CDF) family and the ZIP family. The CDFsection.
family (members of which include ZnT-1 to ZnT-7) medi-The precise role of metal poisoning in vivo is unclear.
ates zinc movement out of cells or into intracellular com-Metal binding to catalytic cysteine residues is reversible
partments for storage and their role has recently beenand can be reversed in the presence of chelating agents,
reviewed elsewhere [105–109]. Members of the ZIPsuch as thionein for zinc [92]. This kind of metal binding
transporter family are found in most organisms. Theymight be understood as part of a control mechanism in
transport zinc ions into mammalian cells and have alsothe presence of elevated concentrations of unbound
been reviewed [110, 111].metal ions. Alternatively, it might provide a protective
Sensing the Concentration of Free Zinc Ions in themechanism for active site cysteines: under normal con-
Cytosol. The human zinc finger protein metal responseditions, concentrations of free zinc in the cytosol are
element binding transcription factor 1 (MTF-1) is an 80usually too low to cause widespread cysteine enzyme
kDa transcription factor containing six Cys2His2 (CCHH)inhibition. In the presence of oxidative stress, however,
zinc fingers [112]. Upon binding zinc, MTF-1 translo-zinc is released from proteins such as metallothionein
cates to the cell’s nucleus, where it binds to the metal(MT) [99], and this increase in cytosolic zinc levels might
responsive element (MRE) of DNA with an apparent DNAthen be sufficient to allow the formation of zinc/sulfur
binding constant of Kapp  3.8  108 M1 (pH 7.0) [113].bonds at the active sites of enzymes such as GAPDH
and caspase-3 [92]. Interestingly, this might prevent Zinc binding to MTF-1 is reversible, with activation of
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Figure 5. Zinc/Sulfur Proteins and Cellular
Zinc Homeostasis
This mechanism is based on recent insights
into the function of MTF-1 and MT and should
be seen in conjunction with other zinc trans-
port proteins such as ZnT-1 to ZnT-7 [105–
109].
MTF-1 DNA binding occurring in the presence of 5 to sists of a single polypeptide chain of approximately 60
amino acids, of which 20 are cysteine residues. Despite15 M of free zinc ions [114]. MTF-1 therefore only
“switches on” once the concentration of unbound cyto- the lack of secondary structure, these residues tightly
bind seven zinc atoms in a Zn3Cys9 and a Zn4Cys11 clustersolic zinc ions reaches or exceeds low M concentra-
tions [115]. Below this “free” zinc concentration, the (see Introduction) [123]. Importantly, these metal ions
are kinetically labile and readily participate in intramo-protein is mostly present in its dissociated, metal-free,
inactive form. Interestingly, free zinc concentrations in lecular metal exchange between the clusters [124] and
can also transfer zinc to a range of apo-proteins suchthe micromolar range are sufficient to inhibit a range of
enzymes, indicating that MTF-1 has an “appropriate” as the apo-forms of bovine carboxypeptidase A, E. coli
alkaline phosphatase, sheep liver sorbitol dehydroge-zinc binding constant to act as a zinc sensor. In its active
form, MTF-1 initiates the expression of metallothionein nase, rat glutocorticoid receptor fragment, and Xenopus
laevis transcription factor TFIIIA [119, 122, 125, 126].I and II genes [116, 117]. Thionein synthesis is therefore
triggered in response to excess zinc (or cadmium) ions, Redox Control of Metal Binding. Metal transfer from
MT to apo-proteins is rather inefficient, with only aboutproviding the cell under “metal stress” with an incredibly
strong metal chelator. one in seven zinc ions transferred in the absence of
mediators such as GSH, citrate, and ATP [119, 125, 127].Lowering the Concentration of Free Zinc Ions. The
exceptionally high thermodynamic stability of MT Due to the presence of 20 cysteine ligands, the zinc/
sulfur clusters are redox sensitive, and ligand oxidation(KD(Zn2) 5 1012 M [pH 7.4] [118]) means that thion-
ein is a strong biological chelating agent that effectively results in zinc release, a process that has been exten-
sively studied in vitro during the last decade [4, 69, 81,binds free zinc ions, thereby lowering the free (but not
overall) zinc concentration in the cytosol [92, 119–121]. 119, 128–131]. Although details of oxidative zinc release
in vivo are not yet established, MT readily undergoesSince thionein is also able to rapidly reactivate enzymes
inhibited by zinc, its role in the control of zinc homeosta- thiol/disulfide exchange reactions with numerous oxi-
dants such as cystine, cystamine, selenocystamine, andsis has been postulated [92, 119, 122]. This suggestion
has recently been supported by studies that have shown glutathione disulfide (GSSG) [99, 119, 125, 128, 131].
Since such reactions involve GSSG and are influencedunexpectedly high concentrations of thionein in cells
[121]. The vast difference in the ability of MTF-1 and MT by GSH, a link between MT, zinc homeostasis, and the
redox state of the cell has been proposed [122]. Theto bind zinc also backs the role of MTF-1 as zinc sensor,
thionein as zinc binding protein, and MT as zinc storage. biological implications of this link are not yet fully under-
stood, and MT has been considered as a zinc storageIt is still not clear, however, if and how thionein would
remove zinc from MTF-1, a process required to fully protein [120, 125] as well as a cellular “redox sensor”
[132].close the feedback circuit of zinc regulation.
Zinc Storage and Exchange. The high thermodynamic The notion of oxidative control of zinc availability
within the cell obviously transcends the role of MT. Zincstability of MT, compared to other zinc proteins (and
particularly MTF-1), allows this protein to function in fingers are known to be sensitive toward oxidation, and
oxidative inhibition of MTF-1 activity would also, directlyintracellular zinc storage. From a chemical point of view,
this high stability is the result of the unique metal/ligand and indirectly, change the availability of zinc ions inside
the cell. Since zinc is also known to upregulate the ex-arrangement found in MT. The mammalian protein con-
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pression of antioxidant enzymes such as Cu,Zn-super- These issues, apart from representing important ad-
vances in rational drug design, also underline the impor-oxide dismutase (Cu,Zn-SOD) [133, 134], oxidative zinc
tance of more fundamental research into cellular redoxrelease is a complex process that invokes many different
and metal trafficking pathways.cellular responses, not all of which are yet fully under-
Redox Drugsstood in vivo.
While healthy human cells maintain a highly reducingRedox Control of Zinc Finger Proteins
intracellular redox environment with GSH:GSSG ratiosApproximately 1% of mammalian genomes encode pro-
around 100:1 [30, 31], disease formation frequently leadsteins containing the zinc finger structural motif that is
to a significantly disturbed redox balance. Disordersbuilt around a zinc/sulfur complex [135]. The most com-
associated with oxidative stress, such as neurodegener-mon class of zinc finger motifs contains zinc ions tetra-
ative diseases, aging, inflammation, rheumatoid arthri-hedrally coordinated to two cysteine and two histidine
tis, diabetes mellitus, and cancer [144–146], are oftenresidues (e.g., transcription factor SP1), although fingers
characterized by high levels of oxidizing species and anwith metal bound to three cysteine and one histidine
impaired antioxidant defense. In contrast, some diseaseresidues (e.g., tumor suppressor p53 [136]) or four cys-
types exhibit abnormally reducing cellular environ-teine residues (e.g., p44 subunit of transcription factor,
ments, especially in malignancies such as the RIF-1TFIIH, estrogen receptor) have also been observed [135,
murine tumor [147]. These abnormal redox states can137]. A unique group of zinc finger proteins are the so-
be used therapeutically by targeting cells with redoxcalled Ring zinc finger proteins that contain two zinc
drugs.ions bound to cysteine and histidine residues within the
There are two main criteria for the design of suchsame domain, e.g., RING finger proteins SAG, ROC, Rbx,
redox agents. First, the drug must be either beneficialand Hrt [138].
or inactive to cells with a normal redox balance. Second,Zinc finger proteins fulfill many biological roles. The
it must be either intrinsically toxic to cells with abnormalfinger motif is abundant in many DNA binding proteins,
redox states or, alternatively, it must become activatedespecially transcription factors (e.g., SP1, TFIIIA, NF-
and thereby exert a toxic effect in response to such akB, MTF-1), where it is a prerequisite for their DNA bind-
redox environment.ing and transcriptional control functions [139]. Oxidation
Reductive activation has been utilized to derive selec-of the cysteine residues leads to the expulsion of the
tive agents for inducing apoptosis or necrosis in malig-zinc, collapse of the zinc finger structure, and inability
nant neoplasms. The interior of such a tumor is deprived
of the transcription factor to bind to DNA [135, 140].
of oxygen due to unregulated growth without vascular
Thus, large parts of the cell’s gene expression and signal
support, creating a hypoxic environment. To overcome
transduction machinery are redox sensitive, which is a this adverse microenvironment, cancer cells must ac-
circumstance that is also increasingly explored in the quire a resistant phenotype, which involves changes in
context of drug design [135, 139, 141, 142] (see Drug enzyme profile and activity [148]. For example, in vivo
Design). DT-diaphorase levels can be increased by as much as
While it is generally true that cysteine oxidation abol- 100-fold in lung adenocarcinoma tissue when compared
ishes metal binding, recent studies have indicated that to normal lung tissue, and even higher fold excesses
there might be notable exceptions to this rule. Cysteine have been reported in vitro for cancer cell lines of the
sulfenic and sulfinic acid have been found in metalloen- colon, breast, and melanoma [149].
zymes such as bacterial nitrile hydratase (NHase), where Bioreductive agents take advantage of this changed
the sulfur acid binds metals such as iron and cobalt [7, phenotype to target these cells. Reducing enzymes such
143]. Oxidized cysteine acids acting as ligands are also as human DT diaphorase, NADH oxidase, and cyto-
being investigated in some transcription factors such chrome c reductase show broad substrate specificity.
as BPV-1 E2 protein and activator protein-1 [39], al- Upon administration of redox-sensitive agents such as
though the details and precise biochemical role of this mitomycin C and diaziquone (Figure 6) in their oxidized
sulfur acid-metal coordination is still under discussion. prodrug forms, they are preferentially reduced in cells
Future studies will without doubt shed more light on the overexpressing these enzymes. Reduction activates the
redox control of metal binding to cysteine ligands and drug, which can then initiate cytotoxic mechanisms such
its biochemical implications. as DNA strand breakage, DNA crosslinking, and produc-
tion of radical species [150].
Importantly, not all cancer cells exhibit such an ex-
Drug Design treme reducing environment. In fact, for some types
The previous sections mentioned examples of metal their redox state can be highly oxidizing. Although most
binding (e.g., MTF-1, thionein) and redox processes cancer cells are in a hypoxic environment, this does
(e.g., oxidative regulation, protection of enzymes) that not necessarily imply the environment is also reducing.
allow cells to respond to changes in their redox environ- Recent studies have demonstrated that cells deprived
ment. The associated area of pharmacological research of oxygen may still possess an overall redox state bal-
is large and this review will focus on a few recent ad- anced in favor of oxidation, due to the inactivation or
vances in redox drugs and metal control. The intention downregulation of antioxidant enzymes such as GPx,
is to show how the issues of redox regulation and metal SOD, and catalase (CAT) and the overactivation of other
control, as discussed in Redox Control, Ligand Oxida- oxidizing pathways such as fatty acid synthesis [151,
tion and Metal Release, and Regulation of Zinc Homeo- 152]. Many cancerous cell types, such as human kidney
stasis, have led to pharmacological research with similar and prostate, therefore, exhibit what would normally be
considered an oxidizing cellular environment [151].biological aims yet a completely different chemistry.
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Figure 6. Drugs Designed to Respond to Redox or Metal Imbalances
Bioreductive (Mitomycin C and Diaziquone), catalytic (4,4’-dihydroxydiphenyltelluride and Ebselen), and metal binding (ethylenediaminetetra-
acetic acid and Feralex-G) compounds that have been proposed to act as therapeutic agents. Details are found in the text.
It has recently been proposed that the administration tions. This results in a cycle of cysteine oxidation and
metal release that is now believed to play a major roleof small, chemically simple redox catalysts that mimic
the catalytic cycle of GPx but lack the enzyme’s high during oxidative stress and (neuronal) disease formation
[161].selectivity for its thiol substrate (primarily GSH) might
provide an avenue to utilize this unusually oxidizing re- Not surprisingly, control of the unbound cytosolic
metal ion concentration provides an alternative to redoxdox environment to inactivate cysteine-containing pro-
teins essential for cancer cell proliferation [153]. A range control. This has led to a range of possible therapeutic
methods, some of which are briefly mentioned in theof GPx mimics such as Ebselen and 4,4’-dihydroxydi-
phenyltelluride (Figure 6) are known to unspecifically next section.
Therapeutic Advances Based on Metal Controlcatalyze the oxidation of various thiols in the presence
of oxidizing agents such as hydrogen peroxide or per- The control of the concentrations of different metal ions
inside the human body is an important area of pharma-oxynitrite [154–156]. In vivo, this might result in a highly
effective, catalytic sensitizing of cells with a disturbed cological research. In conjunction with metal supple-
mentation, metal removal has become part of popularredox balance against their own redox environment,
thereby inducing “cell suicide” without the need of exter- medicine and there is a wealth of literature on the use
of artificial metal binding agents such as ethylenedi-nal stressors such as radiation [153].
Redox catalysis is also an increasingly important area aminetetraacetic acid (EDTA, Figure 6) and their poten-
tial use in medical therapy [162].of antioxidant research. Antioxidants are agents that
effectively counteract the damaging effects of oxidative The administration of metal chelators is clinically ap-
proved for the treatment of metal poisoning. By compet-stressors. Many antioxidants, such as vitamins A, C, and
E, occur naturally and are increasingly used in nutritional ing for the metal ion with biological binding sites, the
chelator can effectively remove excess metal. Chelatorssupplements and for therapeutic purposes [157–159].
Most natural as well as artificial antioxidants can be therefore have two essential characteristics: they must
be specific for the metal ion (and sometimes a particularclassified either as “one shot” antioxidants (reacting
with oxidative stressors in stoichiometric ratios) or cata- oxidation state) they wish to bind, and they must also
have strong binding constants to enable competitivelytic antioxidants. Antioxidant enzymes such as SOD,
CAT, and GPx frequently provide the blueprint for cata- binding. The chelator meso-2,3-dimercaptosuccinic
acid (DMSA), for example, is used therapeutically as alytic antioxidant design, and the therapeutic potential of
metal complexes with SOD and CAT activity is currently drug to reduce blood lead levels in children exposed to
environmental contamination [163]. D-penicillamine isbeing evaluated [160].
The design of antioxidants reflects the vicious cycle clinically used as a copper chelator in the treatment of
Wilson’s disease, which arises due to a metabolic defectof metal release and oxidative stressor formation that
exists during oxidative stress (Figure 6). Since oxidation that results in copper deposition [164]. Glutathione and
-lipoic acid have also been proposed as effectiveof sulfur ligands leads to metal release, adventitious
“free” metals not only oxidize cysteine residues but also chelators for mercury removal [165]. Deferiprone (1,2-
dimethyl-3-hydroxypyrid-4-one) has obtained wide-facilitate hydroxyl radical formation in Fenton-type reac-
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spread clinical use in the treatment of thalassaemia future research and surprising discoveries in the field
of cysteine biochemistry. Recent excitement in peroxire-as a specific iron chelator [166]. A recent advance in
chelation therapy has been the development of drugs doxin research is a good example of this [172–174].
Considering the understanding of regulation and cel-that strongly bind to more than one metal. Fera-
lex-G (2-Deoxy-2-(N-carbamoylmethyl-[N’-2-methyl-3- lular signaling, redox and metal control of cysteine is
likely to play an increasingly important role, and therehydroxy-pyrid-4’-one])-D-glucopyranose, Figure 6) is a
novel chelator for trivalent aluminium and iron that has are several chemically possible regulation mechanisms
that have not yet been identified in proteins. These in-been proposed for the treatment of Alzheimer’s disease.
In vitro, the compound has been shown to dissociate clude sulfur oxidation states less studied in a biological
context, such as sulfenic and sulfinic acids, and thethese metals from hyperphosphorylated tau proteins
[167]. oxidative formation of “unusual” metal binding sites.
The increasing knowledge of cysteine redox transfor-Adventitious iron, copper, and manganese ions have
been implicated in the progression of neurodegenera- mations and how they influence metal binding also has
pronounced effects on the design of future generationstive diseases [144, 161], and the metals have been asso-
ciated with the presence of oxidative stress in these of drugs. Redox transformations are important in many
human disorders, among them diseases related to oxi-disorders. Therefore, in addition to competitively chelat-
ing these species from proteins, there is also intense dative stress. The design of effective antioxidant drugs
is one such promising avenue to control some of theseinterest in removing free metal ions. Agents that strongly
bind these redox active metal ions are currently being problems. In addition, a better understanding of how
cellular redox processes work also paves the way tostudied as potential antioxidants, for example in oxida-
tive stress-related skin damage [168]. While the removal utilize redox or metal imbalances in sick cells to gain a
degree of drug specificity not available at present. Withof adventitious metal ions must be seen in the context of
a range of other reactive species simultaneously present cysteine proteins playing a major role in cell prolifera-
tion, health, and death, this chemistry is likely to beduring oxidative stress, chelate administration might
supplement antioxidant therapy. In some cases, the at the heart of many biochemical and pharmacological
investigations in the future.metal chelator and redox agent might even be one and
the same molecule [169, 170].
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